$CDMO
Avid Bioservices, Inc. Stock $cdmo

$cdmo Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000168316824004610 Filed on July 02, 2024

Income Statement

Concept	2024 Q2	2024	2022
Revenue	$42.98M	$139.9M	$119.6M
YoY Change	7.98%	-6.27%	24.75%
Cost Of Revenue	$37.48M	$132.6M	$82.95M
YoY Change	19.32%	12.57%	24.62%
Gross Profit	$5.500M	$7.318M	$36.65M
YoY Change	-34.45%	-76.75%	25.05%
Gross Profit Margin	12.8%	5.23%	30.64%
Selling, General & Admin	$6.794M	$26.00M	$21.23M
YoY Change	-10.12%	-6.75%	24.39%
% of Gross Profit	123.53%	355.23%	57.92%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$2.859M	$11.11M	$4.480M
YoY Change	51.75%	54.08%	29.74%
% of Gross Profit	51.98%	151.8%	12.22%
Operating Expenses	$6.794M	$26.00M	$21.23M
YoY Change	-10.12%	-6.75%	24.39%
Operating Profit	-$1.294M	-$18.68M	$15.42M
YoY Change	-255.53%	-618.69%	25.97%
Interest Expense	$587.2K	$4.337M	-$2.761M
YoY Change	-177.36%	66.81%	167.8%
% of Operating Profit			-17.9%
Other Income/Expense, Net	-$2.623M	-$3.912M	-$81.00K
YoY Change	-799.52%	-490.42%
Pretax Income	-$5.230M	-$26.93M	$12.66M
YoY Change	-1267.41%	-1444.33%	12.92%
Income Tax	$117.9M	$113.8M	-$115.0M
% Of Pretax Income			-908.39%
Net Earnings	-$123.1M	-$140.8M	$127.7M
YoY Change	39739.48%	-25234.46%	1038.71%
Net Earnings / Revenue	-286.45%	-100.6%	106.75%
Basic Earnings Per Share		-$2.23	$2.08
Diluted Earnings Per Share	-$1.94	-$2.23	$1.812M
COMMON SHARES
Basic Shares Outstanding	63.48M shares	63.20M shares	61.48M shares
Diluted Shares Outstanding		63.20M shares	70.47M shares

Balance Sheet

Concept	2024 Q2	2024	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$38.11M	$38.11M	$126.2M
YoY Change	-1.13%	-1.13%	-25.75%
Cash & Equivalents	$38.11M	$38.11M	$126.2M
Short-Term Investments
Other Short-Term Assets	$6.513M	$6.513M	$1.879M
YoY Change	211.03%	211.03%	76.6%
Inventory	$30.38M	$30.38M	$26.06M
Prepaid Expenses
Receivables	$16.64M	$29.01M	$25.92M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$104.0M	$104.0M	$180.0M
YoY Change	-7.51%	-7.51%	-13.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$186.5M	$227.7M	$129.8M
YoY Change	5.16%	3.42%	131.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.884M	$4.884M	$120.1M
YoY Change	9.19%	-95.88%	7596.09%
Total Long-Term Assets	$232.6M	$232.6M	$249.8M
YoY Change	-31.32%	-31.32%	332.92%
TOTAL ASSETS
Total Short-Term Assets	$104.0M	$104.0M	$180.0M
Total Long-Term Assets	$232.6M	$232.6M	$249.8M
Total Assets	$336.6M	$336.6M	$429.8M
YoY Change	-25.38%	-25.38%	61.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$20.67M	$20.67M	$9.504M
YoY Change	-15.96%	-15.96%	2.67%
Accrued Expenses	$6.791M	$6.791M	$11.39M
YoY Change	-33.01%	-33.01%	12.2%
Deferred Revenue	$39.89M
YoY Change	6.79%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.450M	$1.450M	$505.0K
YoY Change	173.07%	173.07%
Total Short-Term Liabilities	$70.57M	$70.57M	$75.76M
YoY Change	-4.26%	-4.26%	6.8%
LONG-TERM LIABILITIES
Long-Term Debt	$160.7M	$160.7M	$141.7M
YoY Change	13.02%	13.02%	46.13%
Other Long-Term Liabilities	$44.34M	$44.34M	$37.89M
YoY Change	-2.96%	-2.96%	90.49%
Total Long-Term Liabilities	$205.0M	$205.0M	$179.6M
YoY Change	9.13%	9.13%	53.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$70.57M	$70.57M	$75.76M
Total Long-Term Liabilities	$205.0M	$205.0M	$179.6M
Total Liabilities	$275.7M	$275.7M	$255.3M
YoY Change	5.38%	5.38%	35.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$571.9M
YoY Change	32.74%
Common Stock	$64.00K
YoY Change	1.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$60.89M	$60.89M	$174.5M
YoY Change
Total Liabilities & Shareholders Equity	$336.6M	$336.6M	$429.8M
YoY Change	-25.38%	-25.38%	61.89%

Cashflow Statement

Concept	2024 Q2	2024	2022
OPERATING ACTIVITIES
Net Income	-$123.1M	-$140.8M	$127.7M
YoY Change	39739.48%	-25234.46%	1038.71%
Depreciation, Depletion And Amortization	$2.859M	$11.11M	$4.480M
YoY Change	51.75%	54.08%	29.74%
Cash From Operating Activities	$1.257M	$10.95M	$9.465M
YoY Change	-55.09%	-184.98%	-69.65%
INVESTING ACTIVITIES
Capital Expenditures	$5.693M	$31.81M	-$56.41M
YoY Change	-77.12%	-59.03%	471.89%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$5.693M	-$31.81M	-$56.41M
YoY Change	-77.12%	-59.03%	471.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$3.359M
YoY Change			-176.95%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	11.83M	$20.07M	3.197M
YoY Change	1580.97%	591.73%	-97.15%
NET CHANGE
Cash From Operating Activities	1.257M	$10.95M	9.465M
Cash From Investing Activities	-5.693M	-$31.81M	-56.41M
Cash From Financing Activities	11.83M	$20.07M	3.197M
Net Change In Cash	7.398M	-$786.0K	-43.75M
YoY Change	-134.61%	-99.1%	-132.73%
FREE CASH FLOW
Cash From Operating Activities	$1.257M	$10.95M	$9.465M
Capital Expenditures	$5.693M	$31.81M	-$56.41M
Free Cash Flow	-$4.436M	-$20.85M	$65.88M
YoY Change	-79.91%	-76.96%	60.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.84
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62268000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61484000	shares
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	3406000	usd
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0000704562
CY2024Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet		usd
CY2023Q2	cdmo	Deferred Tax Liabilities Net1 DeferredTaxLiabilitiesNet1		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63568000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62692000	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	64000	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	63000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	632696000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	620224000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-571871000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-431118000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	60889000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	189169000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	336557000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	451567000	usd
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	139911000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	149266000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	3872000	usd
CY2024	us-gaap	Variable Lease Cost VariableLeaseCost	1516000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	1408000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	944000	usd
CY2024	us-gaap	Short Term Lease Cost ShortTermLeaseCost	130000	usd
CY2023	cdmo	Unpaid Issuance Costs Associated With Convertible Senior Notes Due2029 UnpaidIssuanceCostsAssociatedWithConvertibleSeniorNotesDue2029		usd
CY2022	cdmo	Unpaid Issuance Costs Associated With Convertible Senior Notes Due2029 UnpaidIssuanceCostsAssociatedWithConvertibleSeniorNotesDue2029		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-04-30
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	false
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	385800000	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	63581054	shares
CY2024	dei	Auditor Firm AuditorFirmId	42
CY2024	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2024	dei	Auditor Location AuditorLocation	Irvine, California
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38106000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38542000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16644000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18298000	usd
CY2024Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	12364000	usd
CY2023Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	9609000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	30375000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	43908000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6513000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2094000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	104002000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	112451000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	186514000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	177770000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	41157000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42772000	usd
CY2023Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	113751000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4884000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4473000	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	350000	usd
CY2024Q2	us-gaap	Assets Assets	336557000	usd
CY2023Q2	us-gaap	Assets Assets	451567000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	20667000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	24593000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5437000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8780000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	39887000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	37352000	usd
CY2024Q2	us-gaap	Convertible Subordinated Debt Current ConvertibleSubordinatedDebtCurrent	0	usd
CY2023Q2	us-gaap	Convertible Subordinated Debt Current ConvertibleSubordinatedDebtCurrent	140623000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1354000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1358000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3221000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	576000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	515000	usd
CY2024	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	361000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	216000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	43000	usd
CY2024	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	342000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	125000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	47000	usd
CY2024	us-gaap	Lease Cost LeaseCost	6924000	usd
CY2023	us-gaap	Lease Cost LeaseCost	6711000	usd
CY2022	us-gaap	Lease Cost LeaseCost	5421000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	41157000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42772000	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	9270000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2529000	usd
CY2024Q2	cdmo	Total Leased Assets TotalLeasedAssets	50427000	usd
CY2023Q2	cdmo	Total Leased Assets TotalLeasedAssets	45301000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1354000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1358000	usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1450000	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	531000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44336000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	45690000	usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7101000	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1562000	usd
CY2024Q2	cdmo	Lease Liability LeaseLiability	54241000	usd
CY2023Q2	cdmo	Lease Liability LeaseLiability	49141000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P15Y8M12D
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P16Y7M6D
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1358000	usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1450000	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	531000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44336000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	45690000	usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7101000	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1562000	usd
CY2024Q2	cdmo	Lease Liability LeaseLiability	54241000	usd
CY2023Q2	cdmo	Lease Liability LeaseLiability	49141000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P15Y8M12D
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P16Y7M6D
CY2024Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P5Y9M18D
CY2023Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060	pure
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060	pure
CY2024Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.065	pure
CY2023Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.053	pure
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	4140000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	4069000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2376000	usd
CY2024	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	294000	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	125000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	47000	usd
CY2024	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	616000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	505000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	162000	usd
CY2024	cdmo	Unpaid Finance Lease Obligation UnpaidFinanceLeaseObligation	339000	usd
CY2023	cdmo	Unpaid Finance Lease Obligation UnpaidFinanceLeaseObligation	0	usd
CY2022	cdmo	Unpaid Finance Lease Obligation UnpaidFinanceLeaseObligation	0	usd
CY2024	cdmo	Rightofuse Assets Obtained Upon Operating Lease Modifications And Reassessments Net RightofuseAssetsObtainedUponOperatingLeaseModificationsAndReassessmentsNet	0	usd
CY2023	cdmo	Rightofuse Assets Obtained Upon Operating Lease Modifications And Reassessments Net RightofuseAssetsObtainedUponOperatingLeaseModificationsAndReassessmentsNet	9267000	usd
CY2022	cdmo	Rightofuse Assets Obtained Upon Operating Lease Modifications And Reassessments Net RightofuseAssetsObtainedUponOperatingLeaseModificationsAndReassessmentsNet	4554000	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2440000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	70566000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	215146000	usd
CY2024Q2	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	153593000	usd
CY2023Q2	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	0	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44336000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	45690000	usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7101000	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1562000	usd
CY2024Q2	cdmo	Deferred Tax Liabilities Net1 DeferredTaxLiabilitiesNet1	72000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	275668000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	262398000	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63568000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63568000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62692000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62692000	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	64000	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	63000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	632696000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	620224000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-571871000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-431118000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	60889000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	189169000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	336557000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	451567000	usd
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	139911000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	149266000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	119597000	usd
CY2024	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	132593000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	117786000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	82949000	usd
CY2024	us-gaap	Gross Profit GrossProfit	7318000	usd
CY2023	us-gaap	Gross Profit GrossProfit	31480000	usd
CY2022	us-gaap	Gross Profit GrossProfit	36648000	usd
CY2024	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25996000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27879000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21226000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	119597000	usd
CY2024	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	132593000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	117786000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	82949000	usd
CY2024	us-gaap	Gross Profit GrossProfit	7318000	usd
CY2023	us-gaap	Gross Profit GrossProfit	31480000	usd
CY2022	us-gaap	Gross Profit GrossProfit	36648000	usd
CY2024	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25996000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27879000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21226000	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	25996000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	27879000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	21226000	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-18678000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	3601000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	15422000	usd
CY2024	us-gaap	Interest Expense InterestExpense	4337000	usd
CY2023	us-gaap	Interest Expense InterestExpense	3013000	usd
CY2022	us-gaap	Interest Expense InterestExpense	2680000	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3912000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1002000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-81000	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26927000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1590000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	12661000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	113826000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1331000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-115011000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-140753000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	259000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	127672000	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-140753000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	259000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	127672000	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.23
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.08
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63199000	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63199000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63782000	shares
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-41621000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	3359000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7380000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	174526000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	3406000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10978000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	259000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	189169000	usd
CY2024	cdmo	Unwinding Of Capped Calls Related To Repurchase Of Convertible Senior Notes Due2026 UnwindingOfCappedCallsRelatedToRepurchaseOfConvertibleSeniorNotesDue2026	1346000	usd
CY2024	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1396000	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9731000	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	25996000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	27879000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	21226000	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-18678000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	3601000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	15422000	usd
CY2023	us-gaap	Interest Expense InterestExpense	3013000	usd
CY2022	us-gaap	Interest Expense InterestExpense	2680000	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3912000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1002000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-81000	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26927000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1590000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	12661000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	113826000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1331000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-115011000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-140753000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	259000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	127672000	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-140753000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	259000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	127672000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.08
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.23
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63199000	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63199000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63782000	shares
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	77736000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-41621000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	3359000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7380000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	127672000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	174526000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	3406000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10978000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	259000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	189169000	usd
CY2024	cdmo	Unwinding Of Capped Calls Related To Repurchase Of Convertible Senior Notes Due2026 UnwindingOfCappedCallsRelatedToRepurchaseOfConvertibleSeniorNotesDue2026	1346000	usd
CY2024	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1396000	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9731000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-140753000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	60889000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-140753000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	259000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	127672000	usd
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11109000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7210000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4480000	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	9731000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	10978000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7380000	usd
CY2024	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1503000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-140753000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	60889000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-140753000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	259000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	127672000	usd
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11109000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7210000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4480000	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	9731000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	10978000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7380000	usd
CY2024	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1503000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1046000	usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	113823000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1331000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-115082000	usd
CY2024	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1865000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2024	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-227000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-139000	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1654000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2249000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1705000	usd
CY2024	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	2755000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	4240000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-743000	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-13533000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	17846000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14191000	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4987000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	61000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4232000	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7133000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	964000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-943000	usd
CY2024	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3343000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	362000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-376000	usd
CY2024	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2535000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-16446000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	3029000	usd
CY2024	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-323000	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1333000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1279000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10952000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12722000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	9465000	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31805000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	77803000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	56411000	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31805000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-77803000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1046000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1030000	usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	113823000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1331000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-115082000	usd
CY2024	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1865000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2024	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-227000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-139000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-381000	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1654000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2249000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1705000	usd
CY2024	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	2755000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	4240000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-743000	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-13533000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	17846000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14191000	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4987000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	61000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4232000	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7133000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	964000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-943000	usd
CY2024	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3343000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-376000	usd
CY2024	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2535000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-16446000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	3029000	usd
CY2024	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-323000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1279000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	10952000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12722000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	9465000	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31805000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	77803000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	56411000	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31805000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-77803000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-56411000	usd
CY2024	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	154281000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2024	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	143750000	usd
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	-0	usd
CY2024	cdmo	Proceeds From Unwinding Of Capped Calls ProceedsFromUnwindingOfCappedCalls	1346000	usd
CY2023	cdmo	Proceeds From Unwinding Of Capped Calls ProceedsFromUnwindingOfCappedCalls	0	usd
CY2022	cdmo	Proceeds From Unwinding Of Capped Calls ProceedsFromUnwindingOfCappedCalls	0	usd
CY2024	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	1396000	usd
CY2023	cdmo	Proceeds From Finance Lease ProceedsFromFinanceLease	0	usd
CY2022	cdmo	Proceeds From Finance Lease ProceedsFromFinanceLease	0	usd
CY2024	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	618000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-56411000	usd
CY2024	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	154281000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2024	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	143750000	usd
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	-0	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	-0	usd
CY2024	cdmo	Proceeds From Unwinding Of Capped Calls ProceedsFromUnwindingOfCappedCalls	1346000	usd
CY2023	cdmo	Proceeds From Unwinding Of Capped Calls ProceedsFromUnwindingOfCappedCalls	0	usd
CY2022	cdmo	Proceeds From Unwinding Of Capped Calls ProceedsFromUnwindingOfCappedCalls	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	3359000	usd
CY2024	cdmo	Proceeds From Finance Lease ProceedsFromFinanceLease	7412000	usd
CY2023	cdmo	Proceeds From Finance Lease ProceedsFromFinanceLease	0	usd
CY2022	cdmo	Proceeds From Finance Lease ProceedsFromFinanceLease	0	usd
CY2024	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	618000	usd
CY2023	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	505000	usd
CY2022	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	162000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20067000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2901000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3197000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-786000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-87624000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-43749000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38892000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126516000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	170265000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126516000	usd
CY2024	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	2564000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	64000	usd
CY2024	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2400000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	14361000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1190000	usd
CY2024	cdmo	Unpaid Issuance Costs Associated With Convertible Senior Notes Due2029 UnpaidIssuanceCostsAssociatedWithConvertibleSeniorNotesDue2029	772000	usd
CY2024Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P5Y9M18D
CY2023Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M12D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060	pure
CY2023	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	505000	usd
CY2022	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	162000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20067000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-786000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-87624000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-43749000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126516000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	170265000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38106000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38892000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126516000	usd
CY2024	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	2564000	usd
CY2022	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	1670000	usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	15000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	260000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	64000	usd
CY2024	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2400000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	14361000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1190000	usd
CY2024	cdmo	Unpaid Issuance Costs Associated With Convertible Senior Notes Due2029 UnpaidIssuanceCostsAssociatedWithConvertibleSeniorNotesDue2029	772000	usd
CY2024Q2	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	0	usd
CY2023Q2	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	400000	usd
CY2024Q2	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	0	usd
CY2023Q2	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	400000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38106000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126166000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	350000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38106000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38892000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126516000	usd
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	139911000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	119597000	usd
CY2024	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	24900000	usd
CY2024	us-gaap	Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	3700000	usd
CY2023	us-gaap	Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	3000000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060	pure
CY2024Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.065	pure
CY2023Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.053	pure
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38106000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38542000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126166000	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	350000	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	350000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38106000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38892000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126516000	usd
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	139911000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	149266000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	119597000	usd
CY2024	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	24900000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	40800000	usd
CY2024	us-gaap	Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	3700000	usd
CY2023	us-gaap	Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	3000000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2300000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	500000	usd
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zSjHutTMwUz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b><span id="xdx_861_z4LPyrfEAVB2">Concentrations of Credit Risk and Customer Base</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents, accounts receivable, net and contract assets. As of April 30, 2024 and 2023, we maintain our cash balances primarily with two major commercial banks and our deposits held with both banks exceed the amount of government insurance limits provided on our deposits. We are exposed to credit risk in the event of default by the major commercial banks holding our cash balances to the extent of the cash amounts recorded on the accompanying consolidated balance sheets exceed the amount of government insurance limits provided on our deposits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our accounts receivable from amounts billed for services provided under customer contracts are derived from a limited number of customers. Most customer contracts require up-front payments and installment payments during the service period. We perform periodic evaluations of the financial condition of our customers and generally do not require collateral, but we can terminate any contract if a material default occurs. At April 30, 2024 and 2023, approximately 67% and 76%, respectively, of our accounts receivable, net were due from our top ten customers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our revenues are derived from a limited number of customers. Historically, these customers have not entered into long-term contracts because their need for drug supply depends on a variety of factors, including a product’s stage of development, the timing of regulatory filings and approvals, the product needs of their collaborators, if applicable, their financial resources and the market demand with respect to a commercial product.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below identifies each of our customers that accounted for 10% or more of our total revenues during any of the fiscal years ended April 30, 2024, 2023 and 2022: </p> <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_pn3n3_zm2SK2eNRByg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Percentage breakdown)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span id="xdx_8B0_zrNjGZdVN43g" style="display: none">Schedule of concentration revenue</span></td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: center"> </td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"> </td><td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"> </td><td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"> </td><td style="font-weight: normal; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Customer</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Geographic Location</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; width: 30%"><span style="font-size: 10pt">Halozyme Therapeutics, Inc. <sup>(1)</sup></span></td><td style="width: 1%; font-weight: normal"> </td> <td style="width: 21%; font-weight: normal; text-align: center">U.S.</td><td style="width: 1%; font-weight: normal"> </td> <td style="width: 1%; font-weight: normal; text-align: left"> </td><td style="width: 13%; font-weight: normal; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230501__20240430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--HalozymeTherapeuticsMember_fKDEp_zFeCeNFBlPEf" title="Customer revenue as a percentage of revenue">33</span>%</td><td style="width: 1%; font-weight: normal; text-align: left"> </td><td style="width: 1%; font-weight: normal"> </td> <td style="width: 1%; font-weight: normal; text-align: left"> </td><td style="width: 13%; font-weight: normal; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20220501__20230430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--HalozymeTherapeuticsMember_fKDEp_zqDABLfZ5JE5" title="Customer revenue as a percentage of revenue">53</span>%</td><td style="width: 1%; font-weight: normal; text-align: left"> </td><td style="width: 1%; font-weight: normal"> </td> <td style="width: 1%; font-weight: normal; text-align: left"> </td><td style="width: 13%; font-weight: normal; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20210501__20220430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--HalozymeTherapeuticsMember_fKDEp_zYIAffGUONe8" title="Customer revenue as a percentage of revenue">41</span>%</td><td style="width: 1%; font-weight: normal; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Coherus BioSciences, Inc.</td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: center">U.S.</td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230501__20240430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CoherusBioSciencesIncMember_zZl98we9JDpf" title="Customer revenue as a percentage of revenue">13</span>%</td><td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif"></span></td><td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif"></span></td><td style="font-weight: normal; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">IGM Biosciences, Inc.</td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: center">U.S.</td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif"></span></td><td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif"></span></td><td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20210501__20220430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--IGMBiosciencesMember_z9e110n2G79i" title="Customer revenue as a percentage of revenue">11</span>%</td><td style="font-weight: normal; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top; text-align: left"> <td style="width: 3%"><span style="font-size: 9pt"><i> </i></span></td> <td style="width: 3%"><span id="xdx_F09_zNeQiHkYEEnj" style="font-size: 9pt"><i><sup>(1)</sup></i></span></td> <td id="xdx_F1B_zn4iFyjL59N5" style="text-align: justify; width: 94%"><span style="font-size: 9pt"><i>Revenues are derived from the manufacture of multiple therapeutics that our customer uses in various products and product candidates.</i></span></td></tr> <tr style="vertical-align: top; text-align: left"> <td><span style="font-size: 9pt"><i> </i></span></td> <td><span style="font-size: 9pt"><i>*</i></span></td> <td style="text-align: justify"><span style="font-size: 9pt"><i>Represents a percentage less than 10% of our total revenues.</i></span></td></tr> </table> <p id="xdx_8A2_zPKTw3JvfuXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.5pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.5pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We attribute revenue to the individual countries where the customer is headquartered. Revenues derived from U.S. based companies were approximately <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230501__20240430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember__srt--StatementGeographicalAxis__country--US_zIg5yFxmta0b" title="Concentration risk percentage">97</span>% for the fiscal year ended April 30, 2024 and approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20220501__20230430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember__srt--StatementGeographicalAxis__country--US_zWiooxhUyME4" title="Concentration risk percentage"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20210501__20220430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember__srt--StatementGeographicalAxis__country--US_zJSr6NJUmb55" title="Concentration risk percentage">100</span></span>% for the fiscal years ended April 30, 2023 and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2300000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	500000	usd
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zSjHutTMwUz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b><span id="xdx_861_z4LPyrfEAVB2">Concentrations of Credit Risk and Customer Base</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents, accounts receivable, net and contract assets. As of April 30, 2024 and 2023, we maintain our cash balances primarily with two major commercial banks and our deposits held with both banks exceed the amount of government insurance limits provided on our deposits. We are exposed to credit risk in the event of default by the major commercial banks holding our cash balances to the extent of the cash amounts recorded on the accompanying consolidated balance sheets exceed the amount of government insurance limits provided on our deposits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our accounts receivable from amounts billed for services provided under customer contracts are derived from a limited number of customers. Most customer contracts require up-front payments and installment payments during the service period. We perform periodic evaluations of the financial condition of our customers and generally do not require collateral, but we can terminate any contract if a material default occurs. At April 30, 2024 and 2023, approximately 67% and 76%, respectively, of our accounts receivable, net were due from our top ten customers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our revenues are derived from a limited number of customers. Historically, these customers have not entered into long-term contracts because their need for drug supply depends on a variety of factors, including a product’s stage of development, the timing of regulatory filings and approvals, the product needs of their collaborators, if applicable, their financial resources and the market demand with respect to a commercial product.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below identifies each of our customers that accounted for 10% or more of our total revenues during any of the fiscal years ended April 30, 2024, 2023 and 2022: </p> <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_pn3n3_zm2SK2eNRByg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Percentage breakdown)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span id="xdx_8B0_zrNjGZdVN43g" style="display: none">Schedule of concentration revenue</span></td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: center"> </td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"> </td><td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"> </td><td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"> </td><td style="font-weight: normal; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Customer</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Geographic Location</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; width: 30%"><span style="font-size: 10pt">Halozyme Therapeutics, Inc. <sup>(1)</sup></span></td><td style="width: 1%; font-weight: normal"> </td> <td style="width: 21%; font-weight: normal; text-align: center">U.S.</td><td style="width: 1%; font-weight: normal"> </td> <td style="width: 1%; font-weight: normal; text-align: left"> </td><td style="width: 13%; font-weight: normal; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230501__20240430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--HalozymeTherapeuticsMember_fKDEp_zFeCeNFBlPEf" title="Customer revenue as a percentage of revenue">33</span>%</td><td style="width: 1%; font-weight: normal; text-align: left"> </td><td style="width: 1%; font-weight: normal"> </td> <td style="width: 1%; font-weight: normal; text-align: left"> </td><td style="width: 13%; font-weight: normal; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20220501__20230430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--HalozymeTherapeuticsMember_fKDEp_zqDABLfZ5JE5" title="Customer revenue as a percentage of revenue">53</span>%</td><td style="width: 1%; font-weight: normal; text-align: left"> </td><td style="width: 1%; font-weight: normal"> </td> <td style="width: 1%; font-weight: normal; text-align: left"> </td><td style="width: 13%; font-weight: normal; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20210501__20220430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--HalozymeTherapeuticsMember_fKDEp_zYIAffGUONe8" title="Customer revenue as a percentage of revenue">41</span>%</td><td style="width: 1%; font-weight: normal; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Coherus BioSciences, Inc.</td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: center">U.S.</td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230501__20240430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CoherusBioSciencesIncMember_zZl98we9JDpf" title="Customer revenue as a percentage of revenue">13</span>%</td><td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif"></span></td><td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif"></span></td><td style="font-weight: normal; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">IGM Biosciences, Inc.</td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: center">U.S.</td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif"></span></td><td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"><span style="font: normal 10pt Times New Roman, Times, Serif"></span></td><td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal"> </td> <td style="font-weight: normal; text-align: left"> </td><td style="font-weight: normal; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20210501__20220430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--IGMBiosciencesMember_z9e110n2G79i" title="Customer revenue as a percentage of revenue">11</span>%</td><td style="font-weight: normal; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top; text-align: left"> <td style="width: 3%"><span style="font-size: 9pt"><i> </i></span></td> <td style="width: 3%"><span id="xdx_F09_zNeQiHkYEEnj" style="font-size: 9pt"><i><sup>(1)</sup></i></span></td> <td id="xdx_F1B_zn4iFyjL59N5" style="text-align: justify; width: 94%"><span style="font-size: 9pt"><i>Revenues are derived from the manufacture of multiple therapeutics that our customer uses in various products and product candidates.</i></span></td></tr> <tr style="vertical-align: top; text-align: left"> <td><span style="font-size: 9pt"><i> </i></span></td> <td><span style="font-size: 9pt"><i>*</i></span></td> <td style="text-align: justify"><span style="font-size: 9pt"><i>Represents a percentage less than 10% of our total revenues.</i></span></td></tr> </table> <p id="xdx_8A2_zPKTw3JvfuXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.5pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 13.5pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We attribute revenue to the individual countries where the customer is headquartered. Revenues derived from U.S. based companies were approximately <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230501__20240430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember__srt--StatementGeographicalAxis__country--US_zIg5yFxmta0b" title="Concentration risk percentage">97</span>% for the fiscal year ended April 30, 2024 and approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20220501__20230430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember__srt--StatementGeographicalAxis__country--US_zWiooxhUyME4" title="Concentration risk percentage"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20210501__20220430__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember__srt--StatementGeographicalAxis__country--US_zJSr6NJUmb55" title="Concentration risk percentage">100</span></span>% for the fiscal years ended April 30, 2023 and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024	us-gaap	Interest Costs Incurred Capitalized InterestCostsIncurredCapitalized	1100000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	223143000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	208138000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	36629000	usd
CY2024	us-gaap	Interest Costs Incurred Capitalized InterestCostsIncurredCapitalized	1100000	usd
CY2023	us-gaap	Interest Costs Incurred Capitalized InterestCostsIncurredCapitalized	800000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	223143000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	208138000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	36629000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	30368000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	186514000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	177770000	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	11100000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7200000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4500000	usd
CY2024	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	100000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	30368000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	186514000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7200000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4500000	usd
CY2024	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	100000	usd
CY2024Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	27600000	usd
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	28700000	usd
CY2024Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4400000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	usd
CY2024Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	27600000	usd
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	28700000	usd
CY2024Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4400000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	usd
CY2024	us-gaap	Advertising Expense AdvertisingExpense	800000	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	700000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	600000	usd
CY2024	us-gaap	Advertising Expense AdvertisingExpense	800000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	600000	usd
CY2024Q2	us-gaap	Deferred Income Taxes And Other Assets Current DeferredIncomeTaxesAndOtherAssetsCurrent	113800000	usd
CY2024Q2	us-gaap	Deferred Income Taxes And Other Assets Current DeferredIncomeTaxesAndOtherAssetsCurrent	113800000	usd
CY2024Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0050	pure
CY2024	cdmo	Purchases Of Capped Calls Related To Convertible Senior Notes PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes	12800000	usd
CY2024Q2	cdmo	Proceeds From Unwinding ProceedsFromUnwinding	1300000	usd
CY2024Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	160000000	usd
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	143750000	usd
CY2024Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0050	pure
CY2024	cdmo	Purchases Of Capped Calls Related To Convertible Senior Notes PurchasesOfCappedCallsRelatedToConvertibleSeniorNotes	12800000	usd
CY2024Q2	cdmo	Proceeds From Unwinding ProceedsFromUnwinding	1300000	usd
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	143750000	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	6407000	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	3127000	usd
CY2024Q2	us-gaap	Convertible Debt ConvertibleDebt	153593000	usd
CY2023Q2	us-gaap	Convertible Debt ConvertibleDebt	140623000	usd
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	4575000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	4386000	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	6407000	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	3127000	usd
CY2023Q2	us-gaap	Convertible Debt ConvertibleDebt	140623000	usd
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	4575000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	4386000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	3872000	usd
CY2024	us-gaap	Variable Lease Cost VariableLeaseCost	1516000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	1408000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	944000	usd
CY2024	us-gaap	Short Term Lease Cost ShortTermLeaseCost	130000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	576000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	515000	usd
CY2024	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	361000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	216000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	43000	usd
CY2024	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	342000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	125000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	47000	usd
CY2024	us-gaap	Lease Cost LeaseCost	6924000	usd
CY2023	us-gaap	Lease Cost LeaseCost	6711000	usd
CY2022	us-gaap	Lease Cost LeaseCost	5421000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	41157000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42772000	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	9270000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2529000	usd
CY2024Q2	cdmo	Total Leased Assets TotalLeasedAssets	50427000	usd
CY2023Q2	cdmo	Total Leased Assets TotalLeasedAssets	45301000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1354000	usd
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	4140000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	4069000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2376000	usd
CY2024	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	294000	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	125000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	47000	usd
CY2024	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	616000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	505000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	162000	usd
CY2024	cdmo	Unpaid Finance Lease Obligation UnpaidFinanceLeaseObligation	339000	usd
CY2023	cdmo	Unpaid Finance Lease Obligation UnpaidFinanceLeaseObligation	0	usd
CY2022	cdmo	Unpaid Finance Lease Obligation UnpaidFinanceLeaseObligation	0	usd
CY2024	cdmo	Rightofuse Assets Obtained Upon Operating Lease Modifications And Reassessments Net RightofuseAssetsObtainedUponOperatingLeaseModificationsAndReassessmentsNet	0	usd
CY2023	cdmo	Rightofuse Assets Obtained Upon Operating Lease Modifications And Reassessments Net RightofuseAssetsObtainedUponOperatingLeaseModificationsAndReassessmentsNet	9267000	usd
CY2022	cdmo	Rightofuse Assets Obtained Upon Operating Lease Modifications And Reassessments Net RightofuseAssetsObtainedUponOperatingLeaseModificationsAndReassessmentsNet	4554000	usd
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	16093000	usd
CY2024	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	0	usd
CY2023	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	89000	usd
CY2022	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	0	usd
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2024Q2	cdmo	Tota Lease Liability Payments Due Next Twelve Months TotaLeaseLiabilityPaymentsDueNextTwelveMonths	6023000	usd
CY2024Q2	cdmo	Tota Lease Liability Payments Due Year Two TotaLeaseLiabilityPaymentsDueYearTwo	6130000	usd
CY2024Q2	cdmo	Tota Lease Liability Payments Due Year Three TotaLeaseLiabilityPaymentsDueYearThree	5953000	usd
CY2024Q2	cdmo	Tota Lease Liability Payments Due Year Four TotaLeaseLiabilityPaymentsDueYearFour	5370000	usd
CY2024Q2	cdmo	Tota Lease Liability Payments Due Year Five TotaLeaseLiabilityPaymentsDueYearFive	5481000	usd
CY2024Q2	cdmo	Tota Lease Liability Payments Due Year Thereafter TotaLeaseLiabilityPaymentsDueYearThereafter	54274000	usd
CY2024Q2	cdmo	Long Term Debt Due LongTermDebtDue	83231000	usd
CY2024Q2	cdmo	Less Imputed Interest LessImputedInterest	28990000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	54241000	usd
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	16093000	usd
CY2024	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	0	usd
CY2023	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	89000	usd
CY2022	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	0	usd
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	2760000	usd
CY2024Q2	cdmo	Tota Lease Liability Payments Due Next Twelve Months TotaLeaseLiabilityPaymentsDueNextTwelveMonths	6023000	usd
CY2024Q2	cdmo	Tota Lease Liability Payments Due Year Two TotaLeaseLiabilityPaymentsDueYearTwo	6130000	usd
CY2024Q2	cdmo	Tota Lease Liability Payments Due Year Three TotaLeaseLiabilityPaymentsDueYearThree	5953000	usd
CY2024Q2	cdmo	Tota Lease Liability Payments Due Year Four TotaLeaseLiabilityPaymentsDueYearFour	5370000	usd
CY2024Q2	cdmo	Tota Lease Liability Payments Due Year Five TotaLeaseLiabilityPaymentsDueYearFive	5481000	usd
CY2024Q2	cdmo	Tota Lease Liability Payments Due Year Thereafter TotaLeaseLiabilityPaymentsDueYearThereafter	54274000	usd
CY2024Q2	cdmo	Long Term Debt Due LongTermDebtDue	83231000	usd
CY2024Q2	cdmo	Less Imputed Interest LessImputedInterest	28990000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	54241000	usd
CY2024Q2	us-gaap	Common Unit Issued CommonUnitIssued	63567998000	shares
CY2024Q2	us-gaap	Common Unit Outstanding CommonUnitOutstanding	63567998000	shares
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	24624000	shares
CY2024Q2	us-gaap	Common Unit Issued CommonUnitIssued	63567998000	shares
CY2024Q2	us-gaap	Common Unit Outstanding CommonUnitOutstanding	63567998000	shares
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	24624000	shares
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	9731000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	10978000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7380000	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	9731000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	10978000	usd
CY2024Q2	us-gaap	Deferred Compensation Liability Current And Noncurrent DeferredCompensationLiabilityCurrentAndNoncurrent	200000	usd
CY2024Q2	us-gaap	Deferred Compensation Liability Current And Noncurrent DeferredCompensationLiabilityCurrentAndNoncurrent	200000	usd
CY2024	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	77000	usd
CY2024	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	3000	usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	77000	usd
CY2024	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3087000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	876000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	7132000	usd
CY2024	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1563000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	455000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	483000	usd
CY2024	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-4650000	usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	1331000	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	7615000	usd
CY2024	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	118473000	usd
CY2023	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-122703000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1331000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-115011000	usd
CY2024	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2024	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	3000	usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	77000	usd
CY2024	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3087000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	876000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	7132000	usd
CY2024	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1563000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	455000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	483000	usd
CY2024	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-4650000	usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	1331000	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	7615000	usd
CY2024	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	118473000	usd
CY2023	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-122703000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	113826000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1331000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-115011000	usd
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5655000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	334000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	2659000	usd
CY2024	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-1329000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	276000	usd
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5655000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	334000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	2659000	usd
CY2024	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-1329000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	276000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	605000	usd
CY2024	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	1188000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	0	usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	0	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	118473000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	0	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-122703000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	615000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1153000	usd
CY2024	cdmo	Income Tax Reconciliation Adjustment For Federal Benefit Of State IncomeTaxReconciliationAdjustmentForFederalBenefitOfState	0	usd
CY2023	cdmo	Income Tax Reconciliation Adjustment For Federal Benefit Of State IncomeTaxReconciliationAdjustmentForFederalBenefitOfState	0	usd
CY2022	cdmo	Income Tax Reconciliation Adjustment For Federal Benefit Of State IncomeTaxReconciliationAdjustmentForFederalBenefitOfState	5326000	usd
CY2024	cdmo	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	84000	usd
CY2023	cdmo	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	66000	usd
CY2022	cdmo	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	425000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	40000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-170000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-115011000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	115420000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	112194000	usd
CY2024Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5571000	usd
CY2023Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5569000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2567000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2589000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	5109000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2420000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	12350000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	12742000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3174000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2360000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	947000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1781000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	145138000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	139655000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	605000	usd
CY2024	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	1188000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	0	usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	0	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	118473000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	0	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-122703000	usd
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	985000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	615000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1153000	usd
CY2024	cdmo	Income Tax Reconciliation Adjustment For Federal Benefit Of State IncomeTaxReconciliationAdjustmentForFederalBenefitOfState	0	usd
CY2023	cdmo	Income Tax Reconciliation Adjustment For Federal Benefit Of State IncomeTaxReconciliationAdjustmentForFederalBenefitOfState	0	usd
CY2022	cdmo	Income Tax Reconciliation Adjustment For Federal Benefit Of State IncomeTaxReconciliationAdjustmentForFederalBenefitOfState	5326000	usd
CY2024	cdmo	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	84000	usd
CY2023	cdmo	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	66000	usd
CY2022	cdmo	Income Tax Reconciliation Permanent Differences IncomeTaxReconciliationPermanentDifferences	425000	usd
CY2024	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	80000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	40000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-170000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	113826000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1331000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-115011000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	115420000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	112194000	usd
CY2024Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5571000	usd
CY2023Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5569000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2567000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2589000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	5109000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2420000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	12350000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3174000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	947000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1781000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	145138000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	118473000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	-0	usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	26665000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	139655000	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	15596000	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	14320000	usd
CY2024Q2	cdmo	Deferred Tax Liabilities Rightofuse Assets DeferredTaxLiabilitiesRightofuseAssets	11124000	usd
CY2023Q2	cdmo	Deferred Tax Liabilities Rightofuse Assets DeferredTaxLiabilitiesRightofuseAssets	11584000	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	17000	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	-0	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	26737000	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	25904000	usd
CY2024Q2	cdmo	Deferred Tax Assets Liabilities Net1 DeferredTaxAssetsLiabilitiesNet1	-72000	usd
CY2023Q2	cdmo	Deferred Tax Assets Liabilities Net1 DeferredTaxAssetsLiabilitiesNet1	113751000	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	118473000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	-0	usd
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	26665000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	139655000	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	15596000	usd
CY2023Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	14320000	usd
CY2024Q2	cdmo	Deferred Tax Liabilities Rightofuse Assets DeferredTaxLiabilitiesRightofuseAssets	11124000	usd
CY2023Q2	cdmo	Deferred Tax Liabilities Rightofuse Assets DeferredTaxLiabilitiesRightofuseAssets	11584000	usd
CY2024Q2	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	17000	usd
CY2024Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	26737000	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	25904000	usd
CY2024Q2	cdmo	Deferred Tax Assets Liabilities Net1 DeferredTaxAssetsLiabilitiesNet1	-72000	usd
CY2023Q2	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	3440000	usd
CY2022Q2	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	5133000	usd
CY2024	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-1840000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-1693000	usd
CY2024Q2	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	1600000	usd
CY2023Q2	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	3440000	usd
CY2024	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-140753000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	259000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	127672000	usd
CY2024	cdmo	Interest Expense Debt1 InterestExpenseDebt1	-0	usd
CY2023	cdmo	Interest Expense Debt1 InterestExpenseDebt1	-0	usd
CY2022	cdmo	Interest Expense Debt1 InterestExpenseDebt1	-1954000	usd
CY2024	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-140753000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	259000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	129626000	usd
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63199000	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62268000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61484000	shares
CY2024	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1248000	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1830000	shares
CY2024	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	266000	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	384000	shares
CY2024	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	6776000	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63199000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63782000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70474000	shares
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.23
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.08
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.23
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.84
CY2023Q2	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	3440000	usd
CY2022Q2	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	5133000	usd
CY2024	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-1840000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-1693000	usd
CY2024Q2	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	1600000	usd
CY2023Q2	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	3440000	usd
CY2024	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-140753000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	259000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	127672000	usd
CY2024	cdmo	Interest Expense Debt1 InterestExpenseDebt1	-0	usd
CY2023	cdmo	Interest Expense Debt1 InterestExpenseDebt1	-0	usd
CY2022	cdmo	Interest Expense Debt1 InterestExpenseDebt1	-1954000	usd
CY2024	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-140753000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	259000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	129626000	usd
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63199000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61484000	shares
CY2024	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1248000	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1830000	shares
CY2024	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	266000	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	384000	shares
CY2024	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	6776000	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63199000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63782000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70474000	shares
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.23
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.08
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.23
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10182000	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7075000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	52000	shares
CY2024	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	1100000	usd
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	900000	usd
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	600000	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7075000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	52000	shares
CY2024	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	1100000	usd
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	900000	usd
CY2022	us-gaap	Deferred Compensation Arrangement With Individual Contributions By Employer DeferredCompensationArrangementWithIndividualContributionsByEmployer	600000	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-004610-index-headers.html	Edgar Link	pending
0001683168-24-004610-index.html	Edgar Link	pending
0001683168-24-004610.txt	Edgar Link	pending
0001683168-24-004610-xbrl.zip	Edgar Link	pending
avid_ex1901.htm	Edgar Link	pending
avid_ex2301.htm	Edgar Link	pending
avid_ex3101.htm	Edgar Link	pending
avid_ex3102.htm	Edgar Link	pending
avid_ex3201.htm	Edgar Link	pending
avid_ex9701.htm	Edgar Link	pending
avid_i10k-043024.htm	Edgar Link	pending
cdmo-20240430.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
cdmo-20240430_def.xml	Edgar Link	unprocessable
cdmo-20240430_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cdmo-20240430_pre.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cdmo-20240430_cal.xml	Edgar Link	unprocessable
avid_i10k-043024_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDMO
Avid Bioservices, Inc. Stock $cdmo

2024 Q2 Form 10-K Financial Statement

#000168316824004610 Filed on July 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDMO Avid Bioservices, Inc. Stock $cdmo

2024 Q2 Form 10-K Financial Statement

#000168316824004610 Filed on July 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDMO
Avid Bioservices, Inc. Stock $cdmo